Blackstone Life Sciences Enters Co-Funding Deal for Acute Myeloid Leukemia Therapy
BXBX•
Blackstone Life Sciences has signed a co-funding agreement to advance development of a novel acute myeloid leukemia therapy. The announcement did not disclose funding amounts or timelines but highlights the scope of Blackstone’s growing oncology investment strategy.
1. Co-Funding Agreement Details
Blackstone Life Sciences announced it has entered a co-funding agreement to support development of a novel therapy for acute myeloid leukemia patients. Financial details, including funding size and partner identity, were not disclosed. The deal reinforces Blackstone’s strategic focus on expanding its life sciences investment portfolio in oncology.
Related News
GOOG
OpenAI Eyes Fall IPO After Lawsuit Win, Battling $900B Anthropic Rival
GOOG•
WPM
Wheaton Precious Metals Publishes Report Highlighting $9.4M Community Investment and MSCI AAA Rating
WPM•
SPY
SpaceX S-1 Filing Reveals $4.7B Q1 Revenue, $1.94B Operating Loss
SPY•
TOL
Toll Brothers Beats Q2 Revenue Guidance by $110M, Raises Delivery and Buyback Plans
TOL•
BBVA
BBVA Joins 25 Banks in 37-Member Qivalis Euro Stablecoin Consortium
BBVA•
Sources
B